$ADAP
Adaptimmune Therapeutics PLC

2020 Q3 Form 10-Q Financial Statement

#000155837020009555 Filed on August 06, 2020

View on sec.gov

Income Statement

Concept 2020 Q3 2020 Q2 2019 Q2
Revenue $1.193M $502.0K $157.0K
YoY Change 403.38% 219.75% -98.26%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $13.00M $10.30M $10.15M
YoY Change 21.04% 1.48% -10.1%
% of Gross Profit
Research & Development $24.07M $20.46M $25.51M
YoY Change -18.74% -19.8% -4.18%
% of Gross Profit
Depreciation & Amortization $1.830M $2.150M $1.970M
YoY Change -6.15% 9.14% 2.6%
% of Gross Profit
Operating Expenses $24.07M $20.46M $25.51M
YoY Change -18.74% -19.8% -4.18%
Operating Profit -$35.88M -$30.25M -$35.50M
YoY Change -10.58% -14.79% 22.94%
Interest Expense $2.150M $970.0K -$5.530M
YoY Change 152.94% -117.54% -62.61%
% of Operating Profit
Other Income/Expense, Net -$1.689M -$749.0K -$6.277M
YoY Change -680.41% -88.07% -59.26%
Pretax Income -$35.42M -$29.86M -$41.02M
YoY Change -9.69% -27.22% -6.22%
Income Tax $15.00K $25.00K $65.00K
% Of Pretax Income
Net Earnings -$35.43M -$29.88M -$41.09M
YoY Change -9.85% -27.28% -6.29%
Net Earnings / Revenue -2969.99% -5952.19% -26170.06%
Basic Earnings Per Share
Diluted Earnings Per Share -$38.18K -$36.32K -$65.29K
COMMON SHARES
Basic Shares Outstanding 928.0M 780.6M
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q3 2020 Q2 2019 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $399.9M $419.0M $133.4M
YoY Change 288.79% 214.07% 3.42%
Cash & Equivalents $78.47M $122.4M $34.57M
Short-Term Investments $321.4M $296.6M $98.83M
Other Short-Term Assets $2.662M $2.929M $599.0K
YoY Change 465.18% 388.98% -98.16%
Inventory
Prepaid Expenses $7.754M $7.903M $8.600M
Receivables $3.809M
Other Receivables $27.00M
Total Short-Term Assets $426.7M $458.1M $175.1M
YoY Change 190.35% 161.57% 8.31%
LONG-TERM ASSETS
Property, Plant & Equipment $26.94M $27.02M $33.72M
YoY Change -14.85% -19.87% -14.63%
Goodwill
YoY Change
Intangibles $1.970M $2.134M $2.066M
YoY Change -13.37% 3.29%
Long-Term Investments
YoY Change
Other Assets $4.600M $6.100M $7.100M
YoY Change -32.35% -14.08% -21.11%
Total Long-Term Assets $52.29M $54.11M $64.39M
YoY Change -14.67% -15.96% 29.81%
TOTAL ASSETS
Total Short-Term Assets $426.7M $458.1M $175.1M
Total Long-Term Assets $52.29M $54.11M $64.39M
Total Assets $479.0M $512.2M $239.5M
YoY Change 130.02% 113.84% 13.36%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.030M $8.766M $4.344M
YoY Change -27.19% 101.8% 5.95%
Accrued Expenses $24.62M $23.84M $18.60M
YoY Change -8.31% 28.18% -11.45%
Deferred Revenue $3.635M $3.464M $3.016M
YoY Change 35.48% 14.85%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $34.90M $38.56M $28.29M
YoY Change -6.69% 36.28% -33.11%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $615.0K $592.0K $571.0K
YoY Change 8.27% 3.68% -85.36%
Total Long-Term Liabilities $615.0K $592.0K $571.0K
YoY Change 8.27% 3.68% -85.36%
TOTAL LIABILITIES
Total Short-Term Liabilities $34.90M $38.56M $28.29M
Total Long-Term Liabilities $615.0K $592.0K $571.0K
Total Liabilities $102.8M $104.6M $52.53M
YoY Change 69.75% 99.15% 13.7%
SHAREHOLDERS EQUITY
Retained Earnings -$549.1M -$513.7M -$387.0M
YoY Change 28.81% 32.74%
Common Stock $1.325M $1.324M $943.0K
YoY Change 40.51% 40.4%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $376.2M $407.6M $187.0M
YoY Change
Total Liabilities & Shareholders Equity $479.0M $512.2M $239.5M
YoY Change 130.02% 113.84% 13.36%

Cashflow Statement

Concept 2020 Q3 2020 Q2 2019 Q2
OPERATING ACTIVITIES
Net Income -$35.43M -$29.88M -$41.09M
YoY Change -9.85% -27.28% -6.29%
Depreciation, Depletion And Amortization $1.830M $2.150M $1.970M
YoY Change -6.15% 9.14% 2.6%
Cash From Operating Activities -$16.32M -$24.92M -$34.17M
YoY Change -44.88% -27.07% -3.37%
INVESTING ACTIVITIES
Capital Expenditures -$800.0K -$530.0K -$1.010M
YoY Change 135.29% -47.52% -18.55%
Acquisitions
YoY Change
Other Investing Activities -$26.77M -$186.5M $19.57M
YoY Change -175.66% -1052.94% -9.44%
Cash From Investing Activities -$27.58M -$187.0M $18.56M
YoY Change -178.71% -1107.54% -8.89%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 470.0K 248.0M 330.0K
YoY Change 75057.58% -62.92%
NET CHANGE
Cash From Operating Activities -16.32M -24.92M -34.17M
Cash From Investing Activities -27.58M -187.0M 18.56M
Cash From Financing Activities 470.0K 248.0M 330.0K
Net Change In Cash -43.43M 36.10M -15.28M
YoY Change -899.82% -336.26% 8.37%
FREE CASH FLOW
Cash From Operating Activities -$16.32M -$24.92M -$34.17M
Capital Expenditures -$800.0K -$530.0K -$1.010M
Free Cash Flow -$15.52M -$24.39M -$33.16M
YoY Change -46.98% -26.45% -2.81%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
927668946
dei Entity Central Index Key
EntityCentralIndexKey
0001621227
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
00-0000000
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
631003568
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2020-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-37368
dei Entity Registrant Name
EntityRegistrantName
ADAPTIMMUNE THERAPEUTICS PLC
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
X0
dei Entity Address Address Line1
EntityAddressAddressLine1
60 Jubilee Avenue, Milton Park
dei Entity Address City Or Town
EntityAddressCityOrTown
Abingdon, Oxfordshire
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
OX14 4RX
dei Entity Address Country
EntityAddressCountry
GB
dei City Area Code
CityAreaCode
44
dei Local Phone Number
LocalPhoneNumber
1235 430000
dei Security12b Title
Security12bTitle
American Depositary Shares, each representing 6 Ordinary Shares, par value £0.001 per share
dei Trading Symbol
TradingSymbol
ADAP
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2020Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
927968286
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
122359000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
50412000
CY2020Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
296629000
CY2019Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
39130000
CY2020Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
39099000
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
30947000
CY2020Q2 us-gaap Assets Current
AssetsCurrent
458087000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
120489000
CY2020Q2 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
4324000
CY2019Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
4496000
CY2020Q2 adap Clinical Materials Noncurrent
ClinicalMaterialsNoncurrent
1744000
CY2019Q4 adap Clinical Materials Noncurrent
ClinicalMaterialsNoncurrent
2503000
CY2020Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
18892000
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
20789000
CY2020Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
26100000
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
23649000
CY2020Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
27020000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
31068000
CY2020Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
2134000
CY2019Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
2198000
CY2020Q2 us-gaap Assets
Assets
512201000
CY2019Q4 us-gaap Assets
Assets
181543000
CY2020Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
8766000
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
6357000
CY2020Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2493000
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2493000
CY2020Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
23836000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
23363000
CY2020Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
3464000
CY2019Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
2128000
CY2020Q2 us-gaap Liabilities Current
LiabilitiesCurrent
38559000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
34341000
CY2020Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
20814000
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
22966000
CY2020Q2 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
44651000
CY2020Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
592000
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
598000
CY2020Q2 us-gaap Liabilities
Liabilities
104616000
CY2019Q4 us-gaap Liabilities
Liabilities
57905000
CY2020Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1038249630
CY2020Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
927668946
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
785857300
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
631003568
CY2020Q2 us-gaap Common Stock Value
CommonStockValue
1324000
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
943000
CY2020Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
928777000
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
585623000
CY2020Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-8805000
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-7264000
CY2020Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-513711000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-455664000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
407585000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
123638000
CY2020Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
512201000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
181543000
CY2020Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
502000
CY2019Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
157000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1263000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
157000
CY2020Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
20460000
CY2019Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
25511000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
41724000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
47530000
CY2020Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10295000
CY2019Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10148000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
19556000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
21921000
CY2020Q2 us-gaap Costs And Expenses
CostsAndExpenses
30755000
CY2019Q2 us-gaap Costs And Expenses
CostsAndExpenses
35659000
us-gaap Costs And Expenses
CostsAndExpenses
61280000
us-gaap Costs And Expenses
CostsAndExpenses
69451000
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-30253000
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-35502000
us-gaap Operating Income Loss
OperatingIncomeLoss
-60017000
us-gaap Operating Income Loss
OperatingIncomeLoss
-69294000
CY2020Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
1147000
CY2019Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
757000
us-gaap Investment Income Interest
InvestmentIncomeInterest
1877000
us-gaap Investment Income Interest
InvestmentIncomeInterest
1709000
CY2020Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-749000
CY2019Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-6277000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
188000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-847000
CY2020Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-29855000
CY2019Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-41022000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-57952000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-68432000
CY2020Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
25000
CY2019Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
65000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
95000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
67000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-29880000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-41087000
us-gaap Net Income Loss
NetIncomeLoss
-58047000
us-gaap Net Income Loss
NetIncomeLoss
-68499000
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.04
CY2019Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.07
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.07
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.11
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
822725556
CY2019Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
629355975
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
781235457
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
628655278
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-29880000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-41087000
us-gaap Net Income Loss
NetIncomeLoss
-58047000
us-gaap Net Income Loss
NetIncomeLoss
-68499000
CY2020Q2 us-gaap Other Comprehensive Income Foreign Currency Translation Adjustment Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent
0
CY2019Q2 us-gaap Other Comprehensive Income Foreign Currency Translation Adjustment Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent
0
us-gaap Other Comprehensive Income Foreign Currency Translation Adjustment Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent
0
us-gaap Other Comprehensive Income Foreign Currency Translation Adjustment Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent
0
CY2020Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
1194000
CY2019Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
4842000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
19105000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
1299000
CY2020Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
0
us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
0
CY2020Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1108000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-20759000
CY2020Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
0
CY2019Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
0
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
0
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
0
CY2020Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
699000
CY2019Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
68000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
113000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
278000
CY2019Q2 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax
0
us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax
0
CY2019Q2 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Before Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax
13000
us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Before Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax
13000
CY2020Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-29095000
CY2019Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-36190000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-59588000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-66935000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
123638000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-28167000
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
894000
CY2020Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
90550000
CY2020Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
17911000
CY2020Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-19651000
CY2020Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-586000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1448000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
186037000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-29880000
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4181000
CY2020Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
243838000
CY2020Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
1194000
CY2020Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1108000
CY2020Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
699000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2624000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
407585000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
246885000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-27412000
CY2019Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
36000
CY2019Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-3543000
CY2019Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
210000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8058000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-70371000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
460000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1202000
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3479000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
219655000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-41087000
CY2019Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
330000
CY2019Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
4842000
CY2019Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
68000
CY2019Q2 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Before Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax
13000
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3196000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
186991000
us-gaap Profit Loss
ProfitLoss
-58047000
us-gaap Profit Loss
ProfitLoss
-68499000
us-gaap Depreciation
Depreciation
3583000
us-gaap Depreciation
Depreciation
3642000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
464000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
333000
us-gaap Share Based Compensation
ShareBasedCompensation
4072000
us-gaap Share Based Compensation
ShareBasedCompensation
6675000
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
2004000
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-1048000
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
718000
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
-166000
adap Increase Decrease In Current Assets
IncreaseDecreaseInCurrentAssets
10104000
adap Increase Decrease In Current Assets
IncreaseDecreaseInCurrentAssets
16851000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-615000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-1263000
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
3571000
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-876000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
49074000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
3060000
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
407000
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
922000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
39931000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
54324000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
298016000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
15983000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-258952000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
36217000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
334388000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
5075000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
366000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
339463000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
366000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-678000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
289000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
71775000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-33499000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
54908000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
72476000
CY2020Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-513700000
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
126683000
CY2019Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
38977000
us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note 1 </b><b style="font-weight:bold;">—</b><b style="font-weight:bold;"> General</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Adaptimmune Therapeutics plc is registered in England and Wales. Its registered office is 60 Jubilee Avenue, Milton Park, Abingdon, Oxfordshire, OX14 4RX, United Kingdom. Adaptimmune Therapeutics plc and its subsidiaries (collectively “Adaptimmune” or the “Company”) is a clinical-stage biopharmaceutical company primarily focused on providing novel cell therapies to people with cancer. We are a leader in the development of T-cell therapies for solid tumors. The Company’s proprietary SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell platform enables it to identify cancer targets, find and genetically engineer T-cell receptors (“TCRs”) against those targets, and produce therapeutic candidates (“SPEAR T-cells”) for administration to patients.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">The Company is subject to a number of risks similar to other biopharmaceutical companies in the early stage of clinical development including, but not limited to, the need to obtain adequate additional funding, possible failure of preclinical programs or clinical programs, the need to obtain marketing approval for its SPEAR T-cells, competitors developing new technological innovations, the need to successfully commercialize and gain market acceptance of the Company’s SPEAR T-cells, the need to develop a reliable commercial manufacturing process, the need to commercialize any T-cell therapies that may be approved for marketing, and protection of proprietary technology. If the Company does not successfully commercialize any of its SPEAR T-cells, it will be unable to generate product revenue or achieve profitability. The Company had an accumulated deficit of </span>$513.7 million as of June 30, 2020.</p>
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(b)          Use of estimates in interim financial statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of interim financial statements, in conformity with U.S. GAAP and SEC regulations, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the interim financial statements and reported amounts of revenues and expenses during the reporting period. Estimates and assumptions are primarily made in relation to the valuation of share options, valuation allowances relating to deferred tax assets, revenue recognition, estimation of the incremental borrowing rate for operating leases, estimating clinical trial expenses and estimating R&amp;D tax and expenditure credits. If actual results differ from the Company’s estimates, or to the extent these estimates are adjusted in future periods, the Company’s results of operations could either benefit from, or be adversely affected by, any such change in estimate.</p>
CY2020Q2 adap Number Of Customers
NumberOfCustomers
2
CY2020Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
502000
CY2019Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
157000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1263000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
157000
CY2020Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
46000000.0
CY2020Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
2100000
CY2020Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
48100000
CY2020Q2 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
400000
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
1200000
CY2020Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-182000
CY2019Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-6403000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
907000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-1013000
CY2020Q2 adap Other Nonoperating Income Expense Other
OtherNonoperatingIncomeExpenseOther
-567000
CY2019Q2 adap Other Nonoperating Income Expense Other
OtherNonoperatingIncomeExpenseOther
126000
adap Other Nonoperating Income Expense Other
OtherNonoperatingIncomeExpenseOther
-719000
adap Other Nonoperating Income Expense Other
OtherNonoperatingIncomeExpenseOther
166000
CY2020Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-749000
CY2019Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-6277000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
188000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-847000
CY2020Q2 adap Clinical Materials Current
ClinicalMaterialsCurrent
1521000
CY2019Q4 adap Clinical Materials Current
ClinicalMaterialsCurrent
1459000
CY2020Q2 us-gaap Other Assets Current
OtherAssetsCurrent
2929000
CY2019Q4 us-gaap Other Assets Current
OtherAssetsCurrent
1809000
CY2020Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
39099000
CY2020Q2 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
168200000
CY2019Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
2000000.0
CY2020Q2 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
26
CY2019Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
1
CY2020Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
0
CY2020Q2 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
26746000
CY2019Q4 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
19284000
CY2020Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
7903000
CY2019Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
8395000
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
30947000
CY2020Q2 adap Accrued Liabilities For Purchases Current
AccruedLiabilitiesForPurchasesCurrent
9219000
CY2019Q4 adap Accrued Liabilities For Purchases Current
AccruedLiabilitiesForPurchasesCurrent
8782000
CY2020Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
9892000
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
6863000
CY2020Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2057000
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2662000
CY2020Q2 us-gaap Recorded Unconditional Purchase Obligation
RecordedUnconditionalPurchaseObligation
2500000
CY2019Q4 us-gaap Recorded Unconditional Purchase Obligation
RecordedUnconditionalPurchaseObligation
5000000
CY2020Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
168000
CY2019Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
56000
CY2020Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
23836000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
23363000
us-gaap Longterm Purchase Commitment Period
LongtermPurchaseCommitmentPeriod
P5Y
CY2020Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2624000
CY2019Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3196000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4072000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6675000
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2738936
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
936696
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
12968216
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
11743896
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.30
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.39
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.47
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.54
CY2020Q2 adap Share Based Compensation Arrangement By Share Based Payment Award Options With Nominal Exercise Price Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWithNominalExercisePriceGrantsInPeriodGross
778120
CY2019Q2 adap Share Based Compensation Arrangement By Share Based Payment Award Options With Nominal Exercise Price Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWithNominalExercisePriceGrantsInPeriodGross
459240
adap Share Based Compensation Arrangement By Share Based Payment Award Options With Nominal Exercise Price Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWithNominalExercisePriceGrantsInPeriodGross
6838816
adap Share Based Compensation Arrangement By Share Based Payment Award Options With Nominal Exercise Price Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWithNominalExercisePriceGrantsInPeriodGross
6957366
CY2020Q2 adap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value With Nominal Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueWithNominalExercisePrice
0.43
CY2019Q2 adap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value With Nominal Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueWithNominalExercisePrice
0.70
adap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value With Nominal Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueWithNominalExercisePrice
0.71
adap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value With Nominal Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueWithNominalExercisePrice
0.93

Files In Submission

Name View Source Status
0001558370-20-009555-index-headers.html Edgar Link pending
0001558370-20-009555-index.html Edgar Link pending
0001558370-20-009555.txt Edgar Link pending
0001558370-20-009555-xbrl.zip Edgar Link pending
adap-20200630.xsd Edgar Link pending
adap-20200630x10q.htm Edgar Link pending
adap-20200630x10q_htm.xml Edgar Link completed
adap-20200630xex31d1.htm Edgar Link pending
adap-20200630xex31d2.htm Edgar Link pending
adap-20200630xex32d1.htm Edgar Link pending
adap-20200630xex32d2.htm Edgar Link pending
adap-20200630_cal.xml Edgar Link unprocessable
adap-20200630_def.xml Edgar Link unprocessable
adap-20200630_lab.xml Edgar Link unprocessable
adap-20200630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending